TherapeuticsMD, Inc. (TXMD)
Market Cap | 36.54M |
Revenue (ttm) | 87.49M |
Net Income (ttm) | -8.67M |
Shares Out | 9.47M |
EPS (ttm) | -1.43 |
PE Ratio | n/a |
Forward PE | 2.29 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 59,757 |
Open | 3.59 |
Previous Close | 3.59 |
Day's Range | 3.44 - 3.90 |
52-Week Range | 1.99 - 21.00 |
Beta | 1.19 |
Analysts | Buy |
Price Target | 5.10 (+32.12%) |
Earnings Date | Mar 30, 2023 |
About TXMD
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR... [Read more]
Full Company ProfileFinancial Performance
In 2021, TherapeuticsMD's revenue was $86.95 million, an increase of 34.03% compared to the previous year's $64.87 million. Losses were -$172.42 million, -6.05% less than in 2020.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for TXMD stock is "Buy." The 12-month stock price forecast is $5.1, which is an increase of 32.12% from the latest price.
News

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women's healthcare company, today announced that it has com...

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women's healthcare company, today announced that it has ent...

TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -53.43% and 30.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

TherapeuticsMD Announces Third Quarter 2022 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today reported financial results for the third qu...

TherapeuticsMD Announces Additional $7 Million Private Placement
BOCA RATON, Fla.

TherapeuticsMD Announces $7 Million Private Placement
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women's healthcare company, announced today that it received a $7 mil...

TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women's healthcare company, announced today the appointment of Dr. Br...

TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 29.28% and 23.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

TherapeuticsMD Announces Second Quarter 2022 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today reported financial results for the Second Qua...

TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that it will report its second quar...

TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women's healthcare company, announced today that it has received a $1...

Why TherapeuticsMD Shares Are Sinking Today?
Women's healthcare company TherapeuticsMD Inc (NASDAQ: TXMD) shares are falling as EW Healthcare Partners did not acquire the required majority of shares of TXMD through the previously announced tende...

TherapeuticsMD's stock falls 41% after tender offer expires
Shares of TherapeuticsMD Inc. TXMD, +8.67% tumbled 41.6% in premarket trading on Wednesday after the women's health company told investors that EW Healthcare Partners' planned acquisition of Therapeut...

TherapeuticsMD Announces Expiration of Tender Offer
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TXMD” or the “Company”) an innovative, leading women's healthcare company, announced today that Athene Merger, Inc., an affili...

EW Healthcare Partners Announces Extension of TherapeuticsMD Tender Offer
TherapeuticsMD has previously stated that absent the successful closing of this transaction, the Company would likely be required to file for protection under Chapter 11. BOCA RATON, Fla.

5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The Leaderboard
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

EW Healthcare Partners Announces Commencement of the Tender Offer for All Outstanding Shares of TherapeuticsMD
NEW YORK , June 6, 2022 /PRNewswire/ -- EW Healthcare Partners (together with its consolidated subsidiaries and affiliates "EW") announced today that its affiliate, Athene Merger Sub, Inc. ("Purchaser...

Investor Alert - The M&A Class Action Firm Announces an Investigation of TherapeuticsMD, Inc. - TXMD
NEW YORK , June 1, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rat...

THERAPEUTICSMD INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TherapeuticsMD, Inc. - TXMD
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of TherapeuticsMD, ...

SHAREHOLDER ALERT: Weiss Law Investigates TherapeuticsMD, Inc.
NEW YORK , May 31, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of TherapeuticsMD, Inc. ("TherapeuticsMD" o...

Here is why TherapeuticsMD jumped 300%
TherapeuticsMD Inc. (NASDAQ: TXMD) surged 300% after the women's healthcare firm announced the signing of a definitive agreement to be purchased by an EW Healthcare Partners affiliate. EW Healthcare P...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TherapeuticsMD, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - May 31, 2022) - Rigrodsky Law, P.A. is investigating TherapeuticsMD, Inc. ("TXMD") (NASDAQ: TXMD) regarding possible breaches of fiduciary duties and other viol...

Why Is TherapeuticsMD (TXMD) Stock Up 360% Today?
TherapeuticsMD (TXMD) stock is rocketing higher on Tuesday following news of an acquisition deal with EW Healthcare Partners. The post Why Is TherapeuticsMD (TXMD) Stock Up 360% Today?

Shareholder Alert: Ademi LLP investigates whether TherapeuticsMD, Inc. has obtained a Fair Price in its transaction with EW Healthcare
MILWAUKEE , May 31, 2022 /PRNewswire/ -- Ademi LLP is investigating TherapeuticsMD (NASDAQ: TXMD) for possible breaches of fiduciary duty and other violations of law in its transaction with EW Healthc...